Drug Trial Radar · NCT07279935
Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC.
Last checked: Nov 20, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
May 26, 2026
Primary completion
May 18, 2030
Study completion May 18, 2030
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Dec 12, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed as a multi-cohort trial based on various patient biomarkers study with the potential to include new study treatment in the future. EGFR-sensitive mutation-positive patients with distant recurrence after adjuvant osimertinib treatment for EGFRm resectable SIB-IIIA NSCLC and scheduled to receive osimertinib plus chemotherapy will be enrolled in cohort 1. In this cohort, approximately 100 patients will be recruited from 25 sites in China. The enrolment period is planned to be approximately 16 months.
Conditions
- Non-small Cell Lung Cancer
Interventions
Osimertinib+cisplatin or carboplatin + pemetrexed EditDrug
Cohort 1 treated with osimertinib 80 mg once daily (QD) in combination with platinum-based chemotherapy cisplatin \[75 mg/m2\] or carboplatin \[AUC5\]) plus pemetrexed (500 mg/m2) on Day 1 every 3 weeks (Q3W) for 4 cycles, followed by osimertinib QD and pemetrexed Q3W till RECIST 1.1-defined progression or until another discontinuation criterion is met.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To assess the efficacy of osimertinib + chemotherapy by evaluation of PFS in patients who had distant recurrence after adjuvant osimertinib.Time frame: Approximately 52 months
Locations
32 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Beijing, China · Not yet recruiting
Research Site
Beijing, China · Recruiting
Research Site
Beijing, China · Recruiting
Research Site
Chengdu, China · Not yet recruiting
Research Site
Chengdu, China · Recruiting
Research Site
Chongqing, China · Recruiting
Research Site
Fuzhou, China · Recruiting
Research Site
Fuzhou, China · Recruiting
Research Site
Guangzhou, China · Recruiting
Research Site
Guangzhou, China · Withdrawn
Research Site
Guangzhou, China · Recruiting
Research Site
Hangzhou, China · Recruiting
Research Site
Hefei, China · Recruiting
Research Site
Hefei, China · Withdrawn
Research Site
Jinan, China · Withdrawn
Research Site
Jinan, China · Recruiting
Research Site
Kunming, China · Withdrawn
Research Site
Nanchang, China · Recruiting
Research Site
Nanjing, China · Withdrawn
Research Site
Nanjing, China · Recruiting
Research Site
Ningbo, China · Recruiting
Research Site
Shanghai, China · Recruiting
Research Site
Shanghai, China · Withdrawn
Research Site
Shanghai, China · Withdrawn
Research Site
Shenyang, China · Recruiting
Research Site
Shenyang, China · Recruiting
Research Site
Tianjin, China · Recruiting
Research Site
Wuhan, China · Recruiting
Research Site
Wuhan, China · Recruiting
Research Site
Xi'an, China · Recruiting
Research Site
Xi'an, China · Withdrawn
Research Site
Zhengzhou, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.